Evidence map›Paper›PMID 30892142›Full record

ArticleCirculation research2019

The Transcription Factor ERG Regulates Super-Enhancers Associated With an Endothelial-Specific Gene Expression Program.

Viktoria Kalna, Youwen Yang, Claire R Peghaire, Karen Frudd, Rebecca Hannah, Aarti V Shah, Lourdes Osuna Almagro, Joseph J Boyle, Berthold Göttgens, Jorge Ferrer and 2 more

Open access · greenAbstract read
In one paragraph

Article in Circulation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 128 citations in OpenAlex.

  1. ELF5-Mediated Enhancer-Promoter Interaction Regulates LALBA Expression in Ovine Mammary Gland.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Super-Enhancers in Placental Development and Diseases.Journal of developmental biology · 2025
    Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Viktoria KalnaFrom the National Heart and Lung Institute (V.K., Y.Y., C.R.P., K.F., A.V.S., L.O.A., J.J.B., A.M.R., G.M.B.), Imperial College London, United Kingdom.
Youwen YangFrom the National Heart and Lung Institute (V.K., Y.Y., C.R.P., K.F., A.V.S., L.O.A., J.J.B., A.M.R., G.M.B.), Imperial College London, United Kingdom.
Claire R PeghaireFrom the National Heart and Lung Institute (V.K., Y.Y., C.R.P., K.F., A.V.S., L.O.A., J.J.B., A.M.R., G.M.B.), Imperial College London, United Kingdom.
Karen FruddFrom the National Heart and Lung Institute (V.K., Y.Y., C.R.P., K.F., A.V.S., L.O.A., J.J.B., A.M.R., G.M.B.), Imperial College London, United Kingdom.
Rebecca HannahDepartment of Haematology, Wellcome Trust and MRC Cambridge Stem Cell Institute, University of Cambridge, United Kingdom (R.H., B.G.).
Aarti V ShahFrom the National Heart and Lung Institute (V.K., Y.Y., C.R.P., K.F., A.V.S., L.O.A., J.J.B., A.M.R., G.M.B.), Imperial College London, United Kingdom.
Lourdes Osuna AlmagroFrom the National Heart and Lung Institute (V.K., Y.Y., C.R.P., K.F., A.V.S., L.O.A., J.J.B., A.M.R., G.M.B.), Imperial College London, United Kingdom.
Joseph J BoyleFrom the National Heart and Lung Institute (V.K., Y.Y., C.R.P., K.F., A.V.S., L.O.A., J.J.B., A.M.R., G.M.B.), Imperial College London, United Kingdom.
Berthold GöttgensDepartment of Haematology, Wellcome Trust and MRC Cambridge Stem Cell Institute, University of Cambridge, United Kingdom (R.H., B.G.).
Jorge FerrerEpigenomics and Disease, Department of Medicine (J.F.), Imperial College London, United Kingdom.
Anna M RandiFrom the National Heart and Lung Institute (V.K., Y.Y., C.R.P., K.F., A.V.S., L.O.A., J.J.B., A.M.R., G.M.B.), Imperial College London, United Kingdom.
Graeme M BirdseyFrom the National Heart and Lung Institute (V.K., Y.Y., C.R.P., K.F., A.V.S., L.O.A., J.J.B., A.M.R., G.M.B.), Imperial College London, United Kingdom.
Imperial College London · GB

Funding

British Heart Foundation FS/13/12/30037British Heart Foundation FS/15/65/32036British Heart Foundation PG/17/33/32990British Heart Foundation RG/11/17/29256British Heart Foundation RG/17/4/32662Cancer Research UK 21762Medical Research Council MC_PC_12009
6 · The paper itself

Abstract

rationaleThe ETS (E-26 transformation-specific) transcription factor ERG (ETS-related gene) is essential for endothelial homeostasis, driving expression of lineage genes and repressing proinflammatory genes. Loss of ERG expression is associated with diseases including atherosclerosis. ERG's homeostatic function is lineage-specific, because aberrant ERG expression in cancer is oncogenic. The molecular basis for ERG lineage-specific activity is unknown. Transcriptional regulation of lineage specificity is linked to enhancer clusters (super-enhancers).

objectiveTo investigate whether ERG regulates endothelial-specific gene expression via super-enhancers. METHODS AND

resultsChromatin immunoprecipitation with high-throughput sequencing in human umbilical vein endothelial cells showed that ERG binds 93% of super-enhancers ranked according to H3K27ac, a mark of active chromatin. These were associated with endothelial genes such as DLL4 (Delta-like protein 4), CLDN5 (claudin-5), VWF (von Willebrand factor), and CDH5 (VE-cadherin). Comparison between human umbilical vein endothelial cell and prostate cancer TMPRSS2 (transmembrane protease, serine-2):ERG fusion-positive human prostate epithelial cancer cell line (VCaP) cells revealed distinctive lineage-specific transcriptome and super-enhancer profiles. At a subset of endothelial super-enhancers (including DLL4 and CLDN5), loss of ERG results in significant reduction in gene expression which correlates with decreased enrichment of H3K27ac and MED (Mediator complex subunit)-1, and reduced recruitment of acetyltransferase p300. At these super-enhancers, co-occupancy of GATA2 (GATA-binding protein 2) and AP-1 (activator protein 1) is significantly lower compared with super-enhancers that remained constant following ERG inhibition. These data suggest distinct mechanisms of super-enhancer regulation in endothelial cells and highlight the unique role of ERG in controlling a core subset of super-enhancers. Most disease-associated single nucleotide polymorphisms from genome-wide association studies lie within noncoding regions and perturb transcription factor recognition sequences in relevant cell types. Analysis of genome-wide association studies data shows significant enrichment of risk variants for cardiovascular disease and other diseases, at ERG endothelial enhancers and super-enhancers.

conclusionsThe transcription factor ERG promotes endothelial homeostasis via regulation of lineage-specific enhancers and super-enhancers. Enrichment of cardiovascular disease-associated single nucleotide polymorphisms at ERG super-enhancers suggests that ERG-dependent transcription modulates disease risk.

Indexed as

Gene Expression ProfilingGene Expression RegulationCell Line, TumorCells, CulturedClaudin-5Enhancer Elements, GeneticGATA2 Transcription FactorHumansHuman Umbilical Vein Endothelial CellsIntracellular Signaling Peptides and ProteinsMaleMembrane ProteinsProstatic NeoplasmsSerine EndopeptidasesTranscriptional Regulator ERGTranscription Factor AP-1Claudin-5CLDN5 protein, humandelta proteinERG protein, humanGATA2 protein, humanGATA2 Transcription FactorIntracellular Signaling Peptides and ProteinsMembrane ProteinsSerine EndopeptidasesTMPRSS2 protein, humanTranscriptional Regulator ERGTranscription Factor AP-1chromatinendothelial cellsendotheliumhomeostasistranscription factors

Identifiers

PMID30892142
PMCPMC6493686
OpenAlexW2924079672

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.